4 results match your criteria: "Urologic Oncology Branch National Cancer Institute[Affiliation]"
Urology
October 2024
Urologic Oncology Branch National Cancer Institute, Bethesda, MD. Electronic address:
Objective: To evaluate MRI-based measurements of androgen-sensitive perineal/pelvic muscles in men with prostate cancer before and after androgen deprivation therapy (ADT) as a novel imaging marker for end-organ effects of hypogonadism. Diagnosing hypogonadism or testosterone deficiency (TD) requires both low serum testosterone and clinical symptoms, such as erectile dysfunction and reduced libido. However, the non-specific nature of many TD symptoms makes it challenging to initiate therapy.
View Article and Find Full Text PDFJ Cancer
July 2021
Translational Surgical Pathology, Laboratory of Pathology, National Institutes of health, Bethesda, MD.
Intratumoral heterogeneity (IH) has been recently described as an important contributor to tumor growth through a branched rather than a linear pattern of tumor evolution for renal cell carcinoma. As to whether the miRNA profiling of the different and heterogeneous areas is the same or not, it is not known. This study analyzed the differences and similarities of the miRNA profiles in histologically distinct regions within several RCC tumors.
View Article and Find Full Text PDFCurr Opin Urol
July 2012
Urologic Oncology Branch National Cancer Institute, National Institute of Health, Bethesda, Maryland, USA.
Purpose Of Review: The advent of prostate-specific antigen screening has led to a seven-fold increase in the incidence of prostate cancer without a resultant decrease in mortality rate. This has led to the belief that urologists are overdetecting and overtreating clinically insignificant disease. To maintain the delicate balance between high cancer cure rate and overtreatment, which could potentially lead to unnecessary morbidities, focal therapy has emerged as the reasonable middle ground.
View Article and Find Full Text PDFJ Clin Endocrinol Metab
December 2000
Urologic Oncology Branch/National Cancer Institute, National Cancer Institute, Bethesda, MD 20892-1501, USA.
In primary hyperaldosteronism, discriminating bilateral adrenal hyperplasia (BAH) from an aldosterone-producing adenoma (APA) is important because adrenalectomy, which is usually curative in APA, is seldom effective in BAH. We analyzed the results from our most recent 7-yr series to evaluate the predictive value of preoperative noninvasive tests compared with adrenal vein sampling (AVS). Forty-eight patients with hypertensive hyperaldosteronism underwent bedside testing, computed tomography (CT) imaging, and AVS.
View Article and Find Full Text PDF